Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Melanoma 22Uveal Melanoma 2Skin Neoplasms 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Lung Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

aldesleukin 23Bevacizumab 17Magnetic Resonance Spectroscopy 15Specimen Handling 12Sunitinib 11Sorafenib 11Interferon-alpha 11cabozantinib 9Cyclophosphamide 9Nivolumab 8Immunoglobulin G 7Disulfides 7temsirolimus 6fludarabine phosphate 5Sirolimus 5Introns 5Fluorouracil 5Erlotinib Hydrochloride 5Chemotherapy, Adjuvant 5sargramostim 4cediranib 4bryostatin 1 4Vorinostat 4Neoadjuvant Therapy 4Ipilimumab 4Interleukin-2 4Interferon alpha-2 4Biopsy 4vandetanib 3ixabepilone 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Carcinoma, Renal Cell × incomplete Freund's adjuvant × Clear all
NCT00001703 2014-07-25

Vaccine Therapy With Tumor Specific Mutated VHL Peptides in Adult Cancer Patients With Renal Cell Carcinoma

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
6 enrolled 8 charts
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡